Conclusion: ADV add-on therapy developed no ADV resistance during the observation period. Therefore, add-on therapy is recommended to LAM-resistant CHB patients with genotype C who have any risk factors for development of ADV resistance: female, liver cirrhosis, and age >45 yr.